It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The airways and alveoli of the human respiratory tract are lined by two distinct types of epithelium, which are the primary targets of respiratory viruses. We previously established long-term expanding human lung epithelial organoids from lung tissues and developed a ‘proximal’ differentiation protocol to generate mucociliary airway organoids. However, a respiratory organoid system with bipotential of the airway and alveolar differentiation remains elusive. Here we defined a ‘distal’ differentiation approach to generate alveolar organoids from the same source for the derivation of airway organoids. The alveolar organoids consisting of type I and type II alveolar epithelial cells (AT1 and AT2, respectively) functionally simulate the alveolar epithelium. AT2 cells maintained in lung organoids serve as progenitor cells from which alveolar organoids derive. Moreover, alveolar organoids sustain a productive SARS-CoV-2 infection, albeit a lower replicative fitness was observed compared to that in airway organoids. We further optimized 2-dimensional (2D) airway organoids. Upon differentiation under a slightly acidic pH, the 2D airway organoids exhibit enhanced viral replication, representing an optimal in vitro correlate of respiratory epithelium for modeling the high infectivity of SARS-CoV-2. Notably, the higher infectivity and replicative fitness of the Omicron variant than an ancestral strain were accurately recapitulated in these optimized airway organoids. In conclusion, we have established a bipotential organoid culture system able to reproducibly expand the entire human respiratory epithelium in vitro for modeling respiratory diseases, including COVID-19.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Li, Cun 1 ; Liu, Xiaojuan 1 ; Yu, Yifei 1 ; Huang, Jingjing 1 ; Wan, Zhixin 1 ; Xiao, Ding 1 ; Chu, Hin 2
; Cai, Jian-Piao 1 ; Zhou, Biao 3 ; Sit, Ko-Yung 4 ; Au, Wing-Kuk 4 ; Wong, Kenneth Kak-Yuen 4 ; Li, Gang 5 ; Chan, Jasper Fuk-Woo 6
; To, Kelvin Kai-Wang 6
; Chen, Zhiwei 7
; Jiang, Shibo 8
; Clevers, Hans 9
; Yuen, Kwok Yung 6
; Zhou, Jie 2
1 The University of Hong Kong, Pokfulam, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757)
2 The University of Hong Kong, Pokfulam, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, State Key Laboratory of Emerging Infectious Diseases, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, China (GRID:grid.194645.b)
3 The University of Hong Kong, AIDS Institute, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757)
4 The University of Hong Kong, and Queen Mary Hospital, Department of Surgery, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757)
5 Southern Medical University, Department of Otolaryngology-Head and Neck Surgery, Precision Medicine Center, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
6 The University of Hong Kong, Pokfulam, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, State Key Laboratory of Emerging Infectious Diseases, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, China (GRID:grid.194645.b); Carol Yu Centre for Infection, The University of Hong Kong, Pokfulam, China (GRID:grid.194645.b) (ISNI:0000000121742757)
7 The University of Hong Kong, Pokfulam, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, State Key Laboratory of Emerging Infectious Diseases, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, AIDS Institute, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757)
8 Fudan University, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443)
9 Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), and University Medical Center (UMC) Utrecht, Utrecht, the Netherlands (GRID:grid.419927.0) (ISNI:0000 0000 9471 3191)




